5-MeO-DET

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
5-MeO-DET
Skeletal formula
Space-filling model of 5-MeO-DET
Identifiers
CAS Number
  • 2454-70-8 No
PubChem CID
  • 417608
ChemSpider
  • 369669 YesY
ChEMBL
  • CHEMBL342986 YesY
Chemical and physical data
Formula C15H22N2O
Molar mass 246.36 g/mol
3D model (JSmol)
  • Interactive image
 NoYesY (what is this?)  (verify)

5-MeO-DET or 5-methoxy-N,N-diethyltryptamine is a hallucinogenic tryptamine.

Pharmacology

5-MeO-DET inhibits serotonin reuptake with an IC50 value of 2.4 µM and activates 5-HT2A receptors with an EC50 value of 8.11 nM.[1][2][3][4][5][6][7]

Effects

Low dosages (0.5–1 mg) are reported to produce a relaxing body high and mild entheogenic effects. Shulgin reports in TiHKAL that higher dosages (1–3 mg) can produce very unpleasant reactions.

See also

References

  1. ^ Meike Schulze-Alexandru; Karl-Artur Kovar; Angelo Vedani (December 1999). "Quasi-atomistic Receptor Surrogates for the 5-HT2A Receptor: A 3D-QSAR Study on Hallucinogenic Substances". Quantitative Structure-Activity Relationships. 18 (6): 548–560. doi:10.1002/(SICI)1521-3838(199912)18:6<548::AID-QSAR548>3.0.CO;2-B. 
  2. ^ Michael B. Gatch; Michael J. Forster; Aaron Janowsky; Amy J. Eshleman (April 2011). "Abuse Liability Profile of Three Substituted Tryptamines". Journal of Pharmacology and Experimental Therapeutics. 338 (1): 280–289. doi:10.1124/jpet.111.179705. PMC 3126641Freely accessible. PMID 21474568. 
  3. ^ Richard A. Glennon; Peter K. Gessner (April 1979). "Serotonin receptor binding affinities of tryptamine analogs". Journal of Medicinal Chemistry. 22 (4): 428–432. doi:10.1021/jm00190a014. PMID 430481. 
  4. ^ Adam L. Halberstadt; Mark A. Geyer (September 2011). "Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens". Neuropharmacology. 61 (3): 364–381. doi:10.1016/j.neuropharm.2011.01.017. PMC 3110631Freely accessible. PMID 21256140. 
  5. ^ P.K. Gessner; D.D. Godse; A.H. Krull; J.M. McMullan (March 1968). "Structure-activity relationships among 5-methoxy-N:N-dimethyltryptamine, 4-hydroxy-N:N-dimethyltryptamine (psilocin) and other substituted tryptamines". Life Sciences. 7 (5): 267–277. doi:10.1016/0024-3205(68)90200-2. 
  6. ^ Robert A. Lyon; Milt Titeler; Mark R. Seggel; Richard A. Glennon (January 1988). "Indolealkylamine analogs share 5-HT2 binding characteristics with phenylalkylamine hallucinogens". European Journal of Pharmacology. 145 (3): 291–297. doi:10.1016/0014-2999(88)90432-3. PMID 3350047. 
  7. ^ Bruce E. Blough; Antonio Landavazo; Ann M. Decker; John S. Partilla; Michael H. Baumann; Richard B. Rothman (October 2014). "Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes". Psychopharmacology. 231 (21): 4135–4144. doi:10.1007/s00213-014-3557-7. PMC 4194234Freely accessible. PMID 24800892. 

External links

  • TiHKAL entry #36
  • 5-MeO-DET entry in TiHKAL • info


Retrieved from "https://en.wikipedia.org/w/index.php?title=5-MeO-DET&oldid=817044693"
This content was retrieved from Wikipedia : http://en.wikipedia.org/wiki/5-MeO-DET
This page is based on the copyrighted Wikipedia article "5-MeO-DET"; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA